Add Yahoo as a preferred source to see more of our stories on Google. Keytruda is authorised for adjuvant treatment of certain RCC patients in EU Merck (MSD) has announced findings from the pivotal ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Cylembio combined with Keytruda improved progression-free survival in advanced melanoma, achieving 19.4 months versus 11.0 months with Keytruda alone. PD-L1 negative patients showed significant ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda ® (pembrolizumab) in combination with other therapies to treat multiple myeloma, ...

Over the years, Merck has run dozens of clinical trials for Keytruda, its groundbreaking cancer immunotherapy. Those studies have earned the drug regulatory approval in 17 types of cancer and helped ...

Thursday, Merck & Co Inc (NYSE:MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

(Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...